Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 26;10(10):e1347. doi: 10.1002/cti2.1347

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Predictive ability of SLAMF8 for anti‐PD1 treatment in clinical practice. Representative image of pretherapeutic SLAMF8 (a) and CD8 (b) protein expression stained by IHC in cancer tissues, with scale bars of 200 μm (left) and 100 μm (right), from patients who obtained the best response of CR, PR, SD and PD, respectively. Comparison of pretherapeutic SLAMF8 (c) and CD8 (d) protein expression between patients with tumors sensitive to (CR + PR) and those with tumors relatively resistant to (SD + PD) anti‐PD1 treatment (n = 8 (CR + PR) for the sensitive group and n = 7 (SD + PD) for the resistant group, **P < 0.01). The relationship between SLAMF8 and CD8 expression (e). Nonstatistical images are from one experiment that is representative of three separate experiments.